The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: A case-control study

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 60-65

  Reichenbach, Adrian ^a   Al Hiti, Hikmet ^a   Malek, Ivan ^a   Pirk, Jan ^a   Goncalvesova, Eva ^b   Kautzner, Josef ^a   Melenovsky, Vojtech ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

Author keywords

Cardiac cachexia; Heart failure; Heart transplantation; Phosphodiesterase 5; Pulmonary hypertension; Sildenafil

Indexed keywords

PHOSPHODIESTERASE V; SILDENAFIL;

ADULT; ARTICLE; BODY WEIGHT; CACHEXIA; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL STATUS; HEART FAILURE; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; LUNG VASCULAR RESISTANCE; MALE; PRESSURE GRADIENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CARDIAC CACHEXIA; HEART FAILURE; HEART TRANSPLANTATION; PULMONARY HYPERTENSION; SILDENAFIL, PHOSPHODIESTERASE 5;

ADULT; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84883775355     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.074     Document Type: Article

References (31)

1. J. Butler, D.B. Chomsky, and J.R. Wilson Pulmonary hypertension and exercise intolerance in patients with heart failure J Am Coll Cardiol 34 1999 1802 1806
2. S. Ghio, A. Gavazzi, and C. Campana Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure J Am Coll Cardiol 37 2001 183 188
3. J.F. Delgado, E. Conde, and V. Sanchez Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure Eur J Heart Fail 7 2005 1011 1016
4. D.L. Moraes, W.S. Colucci, and M.M. Givertz Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management Circulation 102 2000 1718 1723
5. V. Melenovsky, H. Al-Hiti, and L. Kazdova Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil J Am Coll Cardiol 54 2009 595 600
6. A. Costard-Jackle, and M.B. Fowler Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group J Am Coll Cardiol 19 1992 48 54
7. P.R. Forfia, M. Lee, R.S. Tunin, M. Mahmud, H.C. Champion, and D.A. Kass Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart J Am Coll Cardiol 49 2007 1079 1088
8. G.D. Lewis, R. Shah, and K. Shahzad Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension Circulation 116 2007 1555 1562
9. G.D. Lewis, J. Lachmann, and J. Camuso Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure Circulation 115 2007 59 66
10. M. Zakliczynski, M. Maruszewski, and L. Pyka Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates Transplant Proc 39 2007 2856 2858
11. M. Maruszewski, M. Zakliczynski, R. Przybylski, E. Kucewicz-Czech, and M. Zembala Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure Transplant Proc 39 2007 2850 2852
12. A. Jabbour, A. Keogh, C. Hayward, and P. Macdonald Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation Eur J Heart Fail 9 2007 674 677
13. D. Dumitrescu, C. Seck, L. Mohle, E. Erdmann, and S. Rosenkranz Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension Int J Cardiol 154 2012 205 206
14. B.J. Potter, M. White, M. Carrier, M. Pellerin, P.L. L'Allier, and G.B. Pelletier Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the montreal heart institute Can J Cardiol 28 2012 69 73
15. W.C. Levy, D. Mozaffarian, and D.T. Linker The Seattle heart failure model: prediction of survival in heart failure Circulation 113 2006 1424 1433
16. S.D. Anker, A. Negassa, and A.J. Coats Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study Lancet 361 2003 1077 1083
17. M. Guazzi, M. Vicenzi, R. Arena, and M.D. Guazzi Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study Circulation 124 2011 164 174
18. J. Yin, M. Kukucka, and J. Hoffmann Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure Circ Heart Fail 4 2011 198 206
19. H. Al-Hiti, V. Melenovsky, P. Syrovatka, J. Kettner, I. Malek, and J. Kautzner Sildenafil is more selective pulmonary vasodilator than prostaglandin E1 in patients with pulmonary hypertension due to heart failure Physiol Res 60 2011 303 308
20. E. Loh, J.S. Stamler, J.M. Hare, J. Loscalzo, and W.S. Colucci Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction Circulation 90 1994 2780 2785
21. K. Bishu, N. Hamdani, and S.F. Mohammed Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo Circulation 124 2011 2882 2891
22. J.A. Morris-Thurgood, and M.P. Frenneaux Diastolic ventricular interaction and ventricular diastolic filling Heart Fail Rev 5 2000 307 323
23. K. Hirata, A. Adji, C. Vlachopoulos, and M.F. O'Rourke Effect of sildenafil on cardiac performance in patients with heart failure Am J Cardiol 96 2005 1436 1440
24. J. Nagendran, S.L. Archer, and D. Soliman Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Circulation 116 2007 238 248
25. B.A. Borlaug, V. Melenovsky, T. Marhin, P. Fitzgerald, and D.A. Kass Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans Circulation 112 2005 2642 2649
26. J.J. Lepore, A. Maroo, and L.M. Bigatello Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide Chest 127 2005 1647 1653
27. A.A. Ajayi, A.Q. Adigun, E.O. Ojofeitimi, H. Yusuph, and O.E. Ajayi Anthropometric evaluation of cachexia in chronic congestive heart failure: the role of tricuspid regurgitation Int J Cardiol 71 1999 79 84
28. A.J. Genders, E.A. Bradley, S. Rattigan, and S.M. Richards cGMP phosphodiesterase inhibition improves the vascular and metabolic actions of insulin in skeletal muscle Am J Physiol Endocrinol Metab 301 2011 E342 E350
29. J.E. Ayala, D.P. Bracy, B.M. Julien, J.N. Rottman, P.T. Fueger, and D.H. Wasserman Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice Diabetes 56 2007 1025 1033
30. M. Guazzi, G. Tumminello, F. Di Marco, C. Fiorentini, and M.D. Guazzi The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure J Am Coll Cardiol 44 2004 2339 2348
31. A. Behling, L.E. Rohde, F.C. Colombo, L.A. Goldraich, R. Stein, and N. Clausell Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial J Card Fail 14 2008 189 197